This report focuses on the World Health Organization's (WHO) Emergency Use Listing (EUL) of authorized vaccines as of 11 November 2021. Bharat Biotech's new vaccine COVAXIN/ BBV152 received WHO EUL authorisation on 3 November 2021 leading to seven vaccines being now authorised for emergency use: BNT162b2/COMIRNATY (Pfizer-BioNTech, USA), Spikevax/Moderna COVID-19 Vaccine/ mRNA-1273 (Moderna, USA), Vaxzevria/ChAdOx1 nCoV-19/AZD1222/Covishield (AstraZeneca/Oxford, UK, India), Janssen Covid-19 vaccine/Johnson & Johnson (Janssen, USA), Sinopharm/BBIBP-CorV (China), Sinovac/CoronaVac (China), and COVAXIN/BBV152 (Bharat Biotech, India)]. This report provides a condensed summary concerning vaccine efficacy or effectiveness, safety, protection against variants, and further important information for each vaccine in the form of a synoptic table. The data in this synoptic table were extracted from phase III clinical trials and observational studies. This report focuses on the latest data on vaccine effectiveness, breakthrough infections, booster doses, and vaccinations in children.